| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 302.08 mm | 302.08 mm | 302.08 mm | 302.08 mm | 302.08 mm | 302.08 mm |
| Cash burn (monthly) | 2.96 mm | (no burn) | (no burn) | 8.68 mm | 14.55 mm | 12.59 mm |
| Cash used (since last report) | 6.75 mm | n/a | n/a | 19.82 mm | 33.23 mm | 28.74 mm |
| Cash remaining | 295.33 mm | n/a | n/a | 282.26 mm | 268.85 mm | 273.33 mm |
| Runway (months of cash) | 99.9 | n/a | n/a | 32.5 | 18.5 | 21.7 |
| 13F holders | Current |
|---|---|
| Total holders | 185 |
| Opened positions | 43 |
| Closed positions | 24 |
| Increased positions | 75 |
| Reduced positions | 37 |
| 13F shares | Current |
|---|---|
| Total value | 1.49 tn |
| Total shares | 168.50 mm |
| Total puts | 330.20 k |
| Total calls | 429.60 k |
| Total put/call ratio | 0.8 |
| Largest owners | Shares | Value |
|---|---|---|
| Ra Capital Management | 18.20 mm | $225.16 bn |
| GSK GSK | 13.98 mm | $0.00 |
| Adage Capital Management | 9.70 mm | $138.95 mm |
| Adage Capital Partners GP, L.L.C. | 9.62 mm | $119.03 bn |
| Shin Nippon Biomedical Laboratories | 9.61 mm | $18.35 mm |
| BlackRock | 9.36 mm | $115.79 bn |
| Maverick Capital | 8.26 mm | $102.19 bn |
| Driehaus Capital Management | 6.71 mm | $83.03 bn |
| M28 Capital Management | 5.66 mm | $70.07 bn |
| T. Rowe Price | 5.10 mm | $63.07 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Mar 25 | Paul Bolno | Ordinary Shares | Sell | Dispose S | No | Yes | 9.57 | 169,025 | 1.62 mm | 338,351 |
| 7 Mar 25 | Paul Bolno | Ordinary Shares | Option exercise | Acquire M | No | Yes | 2.48 | 169,025 | 419.18 k | 507,376 |
| 7 Mar 25 | Paul Bolno | Share Option Ordinary Shares | Option exercise | Dispose M | No | Yes | 2.48 | 48,059 | 119.19 k | 0 |
| 7 Mar 25 | Paul Bolno | Share Option Ordinary Shares | Option exercise | Dispose M | No | Yes | 2.48 | 120,966 | 300.00 k | 0 |
| 7 Mar 25 | Gregory L. Verdine | Ordinary Shares | Option exercise | Acquire M | No | No | 2.48 | 133,402 | 330.84 k | 312,517 |
| 7 Mar 25 | Gregory L. Verdine | Share Option Ordinary Shares | Option exercise | Dispose M | No | No | 2.48 | 133,402 | 330.84 k | 0 |
| 5 Mar 25 | Gregory L. Verdine | Ordinary Shares | Option exercise | Acquire M | No | No | 2.48 | 133,000 | 329.84 k | 179,155 |
| 5 Mar 25 | Gregory L. Verdine | Share Option Ordinary Shares | Option exercise | Dispose M | No | No | 2.48 | 133,000 | 329.84 k | 133,402 |
| 4 Mar 25 | Chandra Vargeese | Ordinary Shares | Option exercise | Acquire M | No | No | 2.48 | 91,754 | 227.55 k | 362,687 |
| 4 Mar 25 | Chandra Vargeese | Share Option Ordinary Shares | Option exercise | Dispose M | No | No | 2.48 | 75,332 | 186.82 k | 0 |
